Kalvista Pharmaceuticals Inc (KALV)

$11.3

+0.01

(+0.09%)

Market is closed - opens 7 PM, 28 May 2024

Insights on Kalvista Pharmaceuticals Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 67.0% return, outperforming this stock by 47.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 238.7% return, outperforming this stock by 295.2%

Performance

  • $11.15
    $11.44
    $11.30
    downward going graph

    1.33%

    Downside

    Day's Volatility :2.53%

    Upside

    1.22%

    downward going graph
  • $7.21
    $16.88
    $11.30
    downward going graph

    36.19%

    Downside

    52 Weeks Volatility :57.29%

    Upside

    33.06%

    downward going graph

Returns

PeriodKalvista Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
-17.46%
-1.8%
0.0%
6 Months
39.85%
10.1%
0.0%
1 Year
19.2%
13.2%
0.0%
3 Years
-56.45%
17.0%
-21.4%

Highlights

Market Capitalization
476.3M
Book Value
$2.56
Earnings Per Share (EPS)
-3.12
PEG Ratio
0.0
Wall Street Target Price
29.8
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-42.5%
Return On Equity TTM
-79.33%
Revenue TTM
3.8M
Revenue Per Share TTM
0.21
Quarterly Revenue Growth YOY
30.7%
Gross Profit TTM
-80.3M
EBITDA
-107.2M
Diluted Eps TTM
-3.12
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.06
EPS Estimate Next Year
-2.56
EPS Estimate Current Quarter
-0.77
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Kalvista Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 163.72%

Current $11.30
Target $29.80

Technicals Summary

Sell

Neutral

Buy

Kalvista Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Kalvista Pharmaceuticals Inc
Kalvista Pharmaceuticals Inc
4.82%
39.85%
19.2%
-56.45%
-52.76%
Moderna, Inc.
Moderna, Inc.
54.31%
114.37%
31.98%
-5.11%
673.49%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
11.53%
23.42%
35.86%
98.13%
219.88%
Novo Nordisk A/s
Novo Nordisk A/s
7.24%
30.97%
66.95%
238.66%
467.54%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
14.96%
30.49%
38.47%
120.96%
164.5%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Kalvista Pharmaceuticals Inc
Kalvista Pharmaceuticals Inc
NA
NA
0.0
-3.06
-0.79
-0.42
NA
2.56
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.6
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.99
28.99
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.75
46.75
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.23
29.23
0.53
17.14
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Kalvista Pharmaceuticals Inc
Kalvista Pharmaceuticals Inc
Buy
$476.3M
-52.76%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$63.9B
673.49%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
219.88%
28.99
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$605.7B
467.54%
46.75
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$116.3B
164.5%
29.23
39.46%

Institutional Holdings

  • TCG Crossover Management, LLC

    8.05%
  • Suvretta Capital Management, LLC

    6.36%
  • BlackRock Inc

    5.31%
  • Saturn V Capital Management LLC

    4.28%
  • Vanguard Group Inc

    4.22%
  • Boxer Capital LLC

    3.91%

Company Information

kalvista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.

Organization
Kalvista Pharmaceuticals Inc
Employees
118
CEO
Mr. Benjamin L. Palleiko
Industry
Health Technology

FAQs